Figure 2 Cost structure for different perspectives in France (€2005).⁴ The study included 1487 patients with a mean age of 63 and 18 years' disease duration. The mean Health Assessment Questionnaire score was 1.4, mean patient Visual Analogue Scale was 4.4. The sample was slightly biased towards patients treated with anti‐TNF drugs (27% compared to an estimated national 20%).This explains the high proportion of costs represented by the biological treatments. 55% of patients were treated with methotrexate and 28% with other disease‐modifying anti‐rheumatic drugs.